Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial

Harvey D. White, E. Magnus Ohman, A. Michael Lincoff, Michel E. Bertrand, Antonio Colombo, Brent T. McLaurin, David A. Cox, Stuart J. Pocock, James A. Ware, Steven V. Manoukian, Alexandra J. Lansky, Roxana Mehran, Jeffrey W. Moses, Gregg W. Stone

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Background: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrated that in moderate- and high-risk ACS patients undergoing PCI, bivalirudin alone compared to unfractionated heparin (UFH) or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor resulted in less major bleeding and similar ischemic outcomes at 30 days.

Original languageEnglish
Pages (from-to)807-814
Number of pages8
JournalJournal of the American College of Cardiology
Volume52
Issue number10
DOIs
Publication statusPublished - Sep 2 2008

Keywords

  • bivalirudin
  • enoxaparin
  • unfractionated heparin

ASJC Scopus subject areas

  • Nursing(all)

Fingerprint Dive into the research topics of 'Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial'. Together they form a unique fingerprint.

Cite this